Se încarcă compania
Just reported
Q1 FY2027 results
From Phibro Animal Health's results release of 4 noiembrie 2026; its quarterly report has since been filed.
Revenue
Actual
386,8M USD
+6,3 % y/y
-2,5 % q/qGuided
—
No guide given
EPS, GAAP
Actual
0,72 USD
+11 % y/y
+36 % q/qGuided
—
No guide given
EPS, adjusted: 0,79 USD
Operating income, GAAP
Actual
49,6M USD
-3,2 % y/y
+3,1 % q/qGuided
—
No guide given
Company outlook
Q1 FY2027
- Revenue386,8M USD+6,3 % y/y First given
- EPS, adjusted0,79 USDFirst given
- EPS0,72 USDFirst given
Full year 2027
- Revenue1,55B USD – 1,6B USD+3,7 % y/y Unchanged
- EPS, adjusted3,41 USD – 3,59 USDUnchanged
- EPS2,98 USD – 3,22 USDUnchanged
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Phibro Animal Health is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited34,4B USDA
NBIXNeurocrine Biosciences, Inc.16,9B USDA+
ELANElanco Animal Health Incorporated13,4B USDA
KNSAKiniksa Pharmaceuticals International, plc8,2B USDA+
LQDALiquidia Corporation5,2B USDA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct. 2026CAGraded C, now A
Situațiile financiare complete →
Construit din raportările proprii ale Phibro Animal Health Corporation la Comisia pentru Valori Mobiliare și Burse a SUA (SEC). Cifrele sunt cele raportate, iar istoricul pe acțiune este recalculat la baza de acțiuni de azi. Aceasta descrie o afacere — nu este consultanță de investiții și nu este o recomandare de cumpărare sau vânzare.
